Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL.

Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.

2.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.

Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.

PMID:
31239321
3.

Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.

Faden DL, Concha-Benavente F, Chakka AB, McMichael EL, Chandran U, Ferris RL.

Head Neck. 2019 Aug;41(8):2591-2601. doi: 10.1002/hed.25726. Epub 2019 Mar 4.

PMID:
30828910
4.

PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL.

Cancer Immunol Res. 2018 Dec;6(12):1548-1560. doi: 10.1158/2326-6066.CIR-18-0062. Epub 2018 Oct 3.

PMID:
30282672
5.

EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.

Ma W, Concha-Benavente F, Santegoets SJAM, Welters MJP, Ehsan I, Ferris RL, van der Burg SH.

PLoS One. 2018 Sep 7;13(9):e0203402. doi: 10.1371/journal.pone.0203402. eCollection 2018.

6.

STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer.

Lu S, Concha-Benavente F, Shayan G, Srivastava RM, Gibson SP, Wang L, Gooding WE, Ferris RL.

Oral Oncol. 2018 Mar;78:186-193. doi: 10.1016/j.oraloncology.2018.01.019. Epub 2018 Feb 20.

7.

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL.

Cancer Res. 2017 Nov 15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. Epub 2017 Sep 13.

8.

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.

Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, Hechavarría E, González Z, González A, Lugiollo M, Cuevas I, Frómeta C, Mestre BF, Barroso MC, Crombet T, Ferris RL.

Front Pharmacol. 2017 Jun 19;8:382. doi: 10.3389/fphar.2017.00382. eCollection 2017.

9.

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy.

Concha-Benavente F, Ferris RL.

Front Pharmacol. 2017 May 30;8:332. doi: 10.3389/fphar.2017.00332. eCollection 2017. Review.

10.

Oncogenic growth factor signaling mediating tumor escape from cellular immunity.

Concha-Benavente F, Ferris RL.

Curr Opin Immunol. 2017 Apr;45:52-59. doi: 10.1016/j.coi.2017.01.004. Epub 2017 Feb 14. Review.

11.

Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.

Trivedi S, Srivastava RM, Concha-Benavente F, Ferrone S, Garcia-Bates TM, Li J, Ferris RL.

Clin Cancer Res. 2016 Nov 1;22(21):5229-5237. Epub 2016 May 23.

12.

CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.

Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL.

Clin Cancer Res. 2017 Feb 1;23(3):707-716. doi: 10.1158/1078-0432.CCR-16-0879. Epub 2016 Aug 5.

13.

Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.

Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL.

Oral Oncol. 2016 Jul;58:52-8. doi: 10.1016/j.oraloncology.2016.05.008. Epub 2016 Jun 2. Review.

14.

Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice.

Sobo-Vujanovic A, Vujanovic L, DeLeo AB, Concha-Benavente F, Ferris RL, Lin Y, Vujanovic NL.

Cancer Immunol Res. 2016 May;4(5):441-51. doi: 10.1158/2326-6066.CIR-15-0104. Epub 2016 Feb 19.

15.

Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.

Garcia-Bates TM, Kim E, Concha-Benavente F, Trivedi S, Mailliard RB, Gambotto A, Ferris RL.

J Immunol. 2016 Mar 15;196(6):2870-8. doi: 10.4049/jimmunol.1502027. Epub 2016 Feb 5.

16.

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.

Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, Freeman GJ, Ferris RL.

Cancer Res. 2016 Mar 1;76(5):1031-43. doi: 10.1158/0008-5472.CAN-15-2001. Epub 2015 Dec 16.

17.

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF 4th, Ferrone S, Ferris RL.

Cancer Immunol Res. 2015 Aug;3(8):936-45. doi: 10.1158/2326-6066.CIR-15-0053. Epub 2015 May 13.

18.

Immune biomarkers of anti-EGFR monoclonal antibody therapy.

Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt NC, Ferris RL.

Ann Oncol. 2015 Jan;26(1):40-7. doi: 10.1093/annonc/mdu156. Epub 2014 Jul 4. Review.

19.

EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3.

Concha-Benavente F, Srivastava RM, Ferrone S, Ferris RL.

Oncoimmunology. 2013 Dec 1;2(12):e27215. Epub 2013 Dec 5.

Supplemental Content

Loading ...
Support Center